Transcription
Annals ofOncologyAbstract Book of the42nd ESMO Congress (ESMO 2017)Madrid, Spain8–12 September 2017Guest Editors:ESMO 2017 Congress Scientific Committee
Annals of OncologyOfficial Journal of the European Society for Medical Oncology andthe Japanese Society of Medical OncologyEditor-in-chiefJ.-C. Soria, Villejuif, FranceS. Pignata, Naples, ItalyAssociate editorsHematological malignanciesK. Tsukasaki, Saitama, JapanP. L. Zinzani, Bologna, ItalyUrogenital tumorsG. Attard, Sutton, UKM. De Santis, Birmingham, UKGastrointestinal tumorsD. Arnold, Lisbon, PortugalA. Cervantes, Valencia, SpainJ. Tabernero, Barcelona, SpainBreast tumorsF. André, Villejuif, FranceC. Sotiriou, Brussels, BelgiumThoracic tumorsT. Mitsudomi, Osaka, JapanJ. F. Vansteenkiste, Leuven, BelgiumHead and neck tumorsA. T. C. Chan, Shatin, Hong KongE. Cohen, San Diego, California, USAGynecological tumorsB. Monk, Phoenix, Arizona, USABioTechnologiesE. Mardis, St. Louis, Missouri, USAMelanomaG. Long, Sydney, AustraliaOnco-ImmunologyG. Coukos, Lausanne, SwitzerlandA. Snyder, New York, New York, USANeuro-oncologyA. Ibdaih, Paris, FranceSupportive careK. Jordan, Heidelberg, GermanyStatisticsM. Buyse, Brussels, BelgiumEpidemiologyP. Boffetta, New York, New York, USAP. Lagiou, Athens, GreeceMolecular and surgical pathologyI. I. Wistuba, Houston, Texas, USASarcoma and clinical pharmacologyO. Mir, Villejuif, FranceAnnals of Oncology onlineC. Ferté, Villejuif, FranceEarly drug developmentJ.-C. Soria, Villejuif, FranceIndustry corner: perspectives and controversiesK. Dhingra, New York, New York, USAPreclinical and experimental scienceT. U. E. Helleday, Stockholm, SwedenEditors emeritiPrecision medicineC. Swanton, London, UKF. Cavalli, Bellinzona, SwitzerlandD. J. Kerr, Oxford, UKJ. B. Vermorken, Edegem, BelgiumBioinformaticsN. McGranahan, London, UKEditorial boardM. S. Aapro, Genolier, SwitzerlandM. Alsina, Barcelona, SpainY. Ando, Nagoya, JapanP. Autier, Lyon, FranceH. A. Azim Jr, Brussels, BelgiumI. Barnes, Oxford, UKJ. Baselga, New York, USAJ. Bellmunt, Boston, Massachusetts, USAB. Besse, Villejuif, FranceJ. Beyer, Zurich, SwitzerlandP. Bierman, Omaha, Nebraska, USAC. Bokemeyer, Hamburg, GermanyN. Boku, Tokyo, JapanE. Bria, Verona, ItalyE. F. Burgess, Charlotte, USAP. G. Casali, Milan, ItalyF. Ciardiello, Naples, ItalyA. Comandone, Turin, ItalyP. G. Corrie, Cambridge, UKG. Curigliano, Milan, ItalyA. Di Leo, Prato, ItalyR. Dienstmann, Barcelona, SpainT. Dorff, Los Angeles, California, USAH. Dosaka-Akita, Sapporo, JapanA. Eniu, Cluj-Napoca, RomaniaT. Fenske, Milwaukee, Wisconsin, USAS. Galbraith, Cambridge, UKG. Giamas, Brighton, UKR. Glynne-Jones, Northwood, UKB.-C. Goh, SingaporeA. Goldhirsch, Milan, ItalyP. Grimison, Sydney, AustraliaS. I. Ou, Orange, California, USAX. Paoletti, Paris, FranceC. Pezaro, Melbourne, AustraliaP. Pfeiffer, Odense, DenmarkS. Postel-Vinay, Villejuif, FranceA. Psyrri, New Haven, Connecticut, USAD. Quinn, Los Angeles, California, USAS. S. Ramalingam, Atlanta, Georgia, USAM. Reck, Grosshansdorf, GermanyB. Rini, Cleveland, Ohio, USAR. Rosell, Badalona, SpainA. D. Roth, Geneva, SwitzerlandR. Salazar, Barcelona, SpainM. Scartozzi, Ancona, ItalyN. Schmitz, Hamburg, GermanyH.-J. Schmoll, Halle, GermanyI. Sekine, Tsukuba, JapanQ. Shi, Rochester, Minnesota, USAA. F. Sobrero, Genoa, ItalyG. Sonpavde, Birmingham, Alabama, USAS. Takahashi, Tokyo, JapanM. Toi, Kyoto, JapanR. Turck, Montclair, New Jersey, USAB. A. Van Tine, St. Louis, Missouri, USAE. Vilar, Houston, Texas, USAY.-L. Wu, Guangzhou, ChinaJ. C.-H. Yang, Taipei, TaiwanS. Yano, Kanazawa, JapanT. Yoshino, Chiba, JapanA. X. Zhu, Boston, Massachusetts, USAA. Grothey, Rochester, Minnesota, USAS. Halabi, Durham, North Carolina, USAD. G. Haller, Philadelphia, Pennsylvania, USAK. Hotta, Okayama, JapanI. Hyodo, Tsukuba, JapanM. Ignatiadis, Brussels, BelgiumD. H. Ilson, New York, New York, USAH. Iwata, Aichi, JapanF. Janku, Houston, Texas, USAN. Katsumata, Kawasaki, JapanN. Kiyota, Kobe, JapanC. La Vecchia, Milan, ItalyP. N. Jr Lara, Sacramento, California, USAJ. M. Larkin, London, UKS. Loi, Melbourne, AustraliaS. Loibl, Neu-Isenburg, GermanyF. Lordick, Leipzig, GermanyY. Loriot, Villejuif, FranceD. Lorusso, Milan, ItalyS. Lutzker, San Francisco, California, USAT. Macarulla, Barcelona, SpainM. Martin, Madrid, SpainS. Matsui, Tokyo, JapanJ. Maurel, Barcelona, SpainG. McArthur, Melbourne, AustraliaS. Michiels, Villejuif, FranceH. Minami, Kobe, JapanY. Nishimura, Osaka-Sayama, JapanK. Nishio, Osaka-Sayama, JapanM. Ogura, Gifu, JapanA. Ohtsu, Kashiwa, JapanI. Okamoto, Fukuoka, JapanExecutive editor: Lewis RowettEditorial office: Vanessa Marchesi, Paola Minotti Bernasconi, Giovannella Porcu, Annals of Oncology, Via Luigi Taddei 4, CH-6962Viganello-Lugano, SwitzerlandRAnnals of Oncology is covered in C.A.B. International, Current Clinical Cancer, Current Contents/Clinical MedicineV, Current Contents/LifeSciences, Elsevier BIOBASE/Current Awareness in Biological Sciences, EMBASE/Excerpta Medica, IBIDS, Index Medicus/MEDLINE, TheInternational Monitor in Oncology, Medical Documentation Service, Science Citation IndexV and Science Citation Index Expanded.R
SubscriptionsPiscataway, NJ 08854. Periodicals postage paid at Piscataway, NJ and additionalmailing offices.A subscription to Annals of Oncology comprises 12 issues plus supplements ineach volume. Prices include postage, and for subscribers outside the UK delivery isby Standard Air.Subscription records are maintained at Oxford University Press, Oxford, UK.Annual Subscription Rate (Volume 28, 12 issues, 2017)Institutional - Academic / Non profit onlyPrint and Online 1655.00/ 3310.00/f2482.00Online Only 1204.00/ 2408.00/ f1806.00Print Only 1525.00/ 3050.00/f2288.00Institutional - CorporatePrint and Online 2069.00/ 4137.00/f3103.00Online Only 1505.00/ 3010.00/f2258.00Print Only 1906.00/ 3813.00/f2860.00PersonalPrint and Online 1237.00/ 2476.00/f1856.00Please note: US rate applies to US & Canada, Euros applies to Europe, UK applies to UK and Rest of World.There may be other subscription rates available, for a complete listing please visithttps://academic.oup.com/annonc/subscribeFull prepayment, in the correct currency, is required for all orders. Orders areregarded as firm and payments are not refundable. Subscriptions are accepted andentered on a complete volume basis. Claims cannot be considered more than FOURmonths after publication or date of order, whichever is later. All subscriptions inCanada are subject to GST. Subscriptions in the EU may be subject to EuropeanVAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Personal rate subscriptions are only available if payment is made bypersonal cheque or credit card and delivery is to a private address.The current year and two previous years’ issues are available from OxfordJournals. Previous volumes can be obtained from the Periodicals ServiceCompany at http://www.periodicals.com/oxford.html or Periodicals ServiceCompany, 11 Main Street, Germantown, NY 12526, USA. Email: psc@periodicals.com. Tel: (518) 537-4700. Fax: (518) 537-5899For further information, please contact: Journals Customer ServiceDepartment, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP,UK. Email: jnls.cust.serv@oup.com. Tel (and answerphone outside normal working hours): þ44 (0)1865 353907. Fax: þ44 (0)1865 353485. In the US, pleasecontact: Journals Customer Service Department, Oxford University Press, 2001Evans Road, Cary, NC 27513, USA. Email: jnlorders@oup.com. Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada).Fax: 919 677 1714. In Japan, please contact: Journals Customer Service, OxfordUniversity Press, 4-5-10-8F Shiba, Minato-ku, Tokyo 108-8386, Japan. Tel. þ81 35444 5858. Fax. þ81 3 3454 2929. E-mail: custserv. jp@oup.comDOI: For information about DOIs and to resolve them, please visit http://www.doi.orgMethods of payment. (i) Cheque (payable to Oxford University Press, to OxfordUniversity Press, Cashiers Office, Great Clarendon Street, Oxford OX2 6DP, UK)in GB Sterling (drawn on a UK bank), US Dollars (drawn on a US bank), orEUf Euros. (ii) Bank transfer to Barclays Bank Plc, Oxford Group Office, Oxford(bank sort code 20-65-18) (UK), overseas only Swift code BARC GB 22 (GB Sterling to account no. 70299332, IBAN GB89BARC20651870299332; US Dollars to account no. 66014600, IBAN GB27BARC20651866014600; EUf Eurosto account no. 78923655, IBAN GB16BARC20651878923655). (iii) Credit card(Mastercard, Visa, Switch or American Express).Annals of Oncology (ISSN 0923-7534) is published monthly by Oxford UniversityPress, Oxford, UK and distributed in the USA by Central Mailing Services c/oUKP Worldwide, 1637 Stelton Road B2, Piscataway, NJ 08854. The US annualprint subscription or price is 3310.00. Airfreight and mailing in the USA by agentnamed Central Mailing Services c/o UKP Worldwide, 1637 Stelton Road B1-2,Supplements, reprints and corporate salesFor requests from industry and companies regarding supplements, bulk articlereprints, sponsored subscriptions, translation opportunities for previously publishedmaterial, and corporate online opportunities, please email: special. sales@oup.com,fax: þ44 (0) 1865 353774 or visit rmissionsFor information on how to request permissions to reproduce articles/informationfrom this journal, please visit hase/rights and permissions.AdvertisingAdvertising, inserts and artwork enquiries should be addressed to Advertising andSpecial Sales, Oxford Journals, Oxford University Press, Great Clarendon Street,Oxford, OX2 6DP, UK. Tel: þ44 (0)1865 354767; Fax þ44 (0)1865 353774;E-mail: jnlsadvertising@oup.comEnvironmental and ethical policiesOxford Journals, a division of Oxford University Press, is committed to workingwith the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementingenvironmentally friendly policies and practices wherever possible. Please seehttps://academic.oup.com/journals/pages/about us/ethical policies for furtherinformation on environmental and ethical policies.NoticeThe content of the abstracts contained in this Abstract Book is subject to anembargo.Abstracts accepted for presentation at ESMO 2017 as Proffered Paper (oral presentation), Poster Discussion and Poster will be published online on the ESMOwebsite at 00:05 CEST on Thursday, 31 August 2017.Late-breaking abstracts and abstracts selected for the Press Programme will bemade public at 00:05 CEST (Central European Summer Time) on the day of theofficial Congress session during which they are presented.DisclaimerNo responsibility is assumed by the organizers for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or fromany use or operation of any methods, products, instructions or ideas contained in thematerial herein. Because of the rapid advances in medical sciences, we recommendthat independent verification of diagnoses and drug dosages should be made.Every effort has been made to faithfully reproduce the abstracts as submitted.However, no responsibility is assumed by the organizers for any omissions ormisprints.C The European Society for Medical Oncology 2017VAll rights reserved; no part of this publication may be reproduced, stored in aretrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of thePublishers, or a licence permitting restricted copying issued in the UK by theCopyright Licensing Agency Ltd, 90 Tottenham Court Road, London WIP 9HE,or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers,MA 01923.Typeset by Cenveo Publisher Services, Bangalore, India.Printed by Bell and Bain Ltd., Glasgow, UK.
Annals ofOncologyOfficial Journal of theEuropean Society for MedicalOncologyVolume 28, 2017 Supplement 5Abstract Book of the42nd ESMO Congress (ESMO 2017)Madrid, Spain8–12 September 2017Guest Editors:ESMO 2017 Congress Scientific Committee
Annals of OncologyOfficial Journal of the European Societyfor Medical OncologyVolume 28, 2017 Supplement 5Abstract Book of the 42nd ESMO Congress (ESMO 2017)8–12 September 2017, Madrid, SpainAbout ESMOAbout EACRESMO Executive BoardEACR Executive BoardESMO 2017 Congress OfficersAcknowledgementsSubmitted abstractsBasic scienceBiomarkersBreast cancer, early stageBreast cancer, locally advancedBreast cancer, metastaticCNS tumoursDevelopmental therapeuticsEndocrine and neuroendocrine tumoursGastrointestinal tumours, colorectalGastrointestinal tumours, non-colorectalGenitourinary tumours, prostateGenitourinary tumours, non-prostateGynaecological cancersHaematological malignanciesHead and neck cancer, excluding thyroidHealth economicsImmunotherapy of cancerMelanoma and other skin tumoursNew diagnostic toolsNSCLC, early stageNSCLC, locally advancedNSCLC, metastaticPalliative carePrevention and screeningPsycho-oncologyPublic healthSarcomaSCLCSupportive careThoracic malignancies, otherTranslational researchTumour biology and 2v543-v567v568-v572v573-v594v595-v604Note: Abstract suffixes“O” indicates a submitted abstract accepted for Proffered Paper (oral) presentation“PD” indicates a submitted abstract accepted for Poster Discussion presentation“P” indicates a submitted abstract accepted for Poster Presentation“TiP” indicates a submitted abstract accepted for Poster Presentation, Trial in ProgressPR indicates a submitted abstract selected for inclusion in the ESMO Press ProgrammeVolume 28 Supplement 5 September 2017
The European Society for Medical Oncology (ESMO)ESMO is the leading professional organisation for medical oncology, with the overarching goal of improving outcomes for cancerpatients everywhere. We are the society of reference for oncology education and information, and are committed to supporting ourmembers to develop and advance in a fast-evolving professional environment.Founded in 1975, ESMO has European roots with a global reach: we welcome oncology professionals from around the world. We are ahome for all oncology stakeholders, connecting professionals with diverse expertise and experience, and speaking with one voice forour discipline. Our education and information resources support an integrated multi-professional approach to cancer care, from amedical oncology perspective. We seek to erase boundaries in cancer care, whether between countries or specialities, and pursue ourmission across oncology, worldwide.The ESMO community brings together more than 16,000 oncology professionals from over 130 countries. Drawing on 40 years ofexperience and around 500 expert committee members, ESMO serves its members and the oncology community through: Post-graduate oncology education and trainingCareer development and leadership training for the next generations of oncologistsInternational congresses and workshops to share expertise and best practice, learn about the most up-to-date scientific advances,and connect with colleagues in related disciplines.Continuously reviewed, evidence-based standards for cancer care in EuropeAdvocacy and consultation to foster a favourable environment for scientific researchCancer care is rapidly becoming more integrated and more specialised; whether their field is research, diagnosis, treatment, care, oradvocacy, oncology professionals need to both build their specialist knowledge and connect with the best practitioners in other disciplines worldwide. ESMO membership makes this possible.Please visit esmo.org to learn more. Across Oncology. Worldwide.The European Association for Cancer Research (EACR)The European Association for Cancer Research is a professional membership society for cancer researchers with more than 10,000members worldwide. The EACR was founded in 1968 and has one guiding aim: ‘The advancement of cancer research for the publicbenefit’. Membership is open to anyone actively working or studying in cancer research. Our members work across the full spectrum ofthe field, from basic through to translational and clinical research, and range from postgraduate students to winners of the Nobel Prize.Researchers who are members of one of the 14 EACR affiliated ‘National Societies’ automatically become members of the EACR aspart of the wider benefits of belonging to their national society. The membership fee for active members is just 40 Euros per annum or120 Euros for 4 years, and special reduced membership fees are available to postgraduate students and those with less than 4 years’ postdoctoral experience.We facilitate communication and collaboration within the cancer research community. We also set out to raise the profile of cancerresearch in Europe and to make the case for sustained political and economic support. We organise scientific conferences of the highestquality, open to members and non-members. Our Conference Series of small, focused meetings is highly regarded for its focus on thelatest research topics and for the provision of opportunities for interaction between speakers and participants. In 2018 we will celebrateour 50th anniversary and invite you to join us at EACR25, our biennial Congress to be held in Amsterdam, Netherlands, 30 June - 03July 2018.Find out more about the EACR at www.eacr.org
ESMO Executive BoardPresidentPresident-ElectPast President and Membership Committee ChairTreasurerEducational Committee ChairNational Representatives and Membership Committee ChairEU Policy Committee ChairGlobal Policy Committee ChairGuidelines Working Group ChairPress and Media Affairs Committee ChairBoard MemberBoard MemberBoard MemberBoard MemberBoard MemberFortunato Ciardiello, Naples, ItalyJosep Tabernero, Barcelona, SpainRolf A. Stahel, Zurich, SwitzerlandEmile Voest, Amsterdam, NetherlandsAndrés Cervantes, Valencia, SpainFatima Cardoso, Lisbon, PortugalPaolo G. Casali, Milan, ItalyAlexandru Eniu, Cluj-Napoca, RomaniaGeorge Pentheroudakis, Ioannina, GreeceSolange Peters, Lausanne, SwitzerlandDirk Arnold, Lisbon, PortugalSusana Banerjee, London, United KingdomAlexander M. M. Eggermont, Villejuif, FranceSumitra Thongprasert, Bangkok, ThailandChristoph Zielinski, Vienna, AustriaEACR Executive BoardPresidentPresident ElectPast PresidentSecretary erRepresentative for Early Career ResearchersRepresentative for Early Career ResearchersAnton Berns, Amsterdam, NetherlandsAlberto Bardelli, Turin, ItalyRichard Marais, Manchester, UKJoan Seoane, Barcelona, SpainChristof von Kalle, Heidelberg, GermanyCarlos Caldas, Cambridge, UKLeonor David, Porto, PortugalCaroline Dive, Manchester, UKDaniel Peeper, Amsterdam, NetherlandsYardena Samuels, Rehovot, IsraelEmmy Verschuren, Helsinki, FinlandEli Pikarsky, Jerusalem, IsraelTherese Sørlie, Oslo, Norway
ESMO 2017 Congress OfficersESMO and Congress PresidentFortunato Ciardiello, Naples, ItalyScientific Committee Co-ChairsAlberto Sobrero, Genoa, Italy (ESMO)Richard Marais, Manchester, UK (EACR)Educational ChairAndrés Cervantes, Valencia, SpainPress OfficerSolange Peters, Lausanne, SwitzerlandLocal OfficerMiguel Martin, Madrid, SpainScientific CommitteeBasic scienceChairs: Anton Berns, Amsterdam, Netherlands andChristof von Kalle, Heidelberg, GermanyAlberto Bardelli, Candiolo, ItalyRaffaele Califano, Manchester, UKKarin de Visser, Amsterdam, NetherlandsKristian Helin, Copenhagen, DenmarkDavid Huntsman, Vancouver, BC, CanadaClare Isacke, Cambridge, UKRichard Marais, Manchester, UKUltan McDermott, Cambridge, UKPier Guiseppe Pelicci, Milan, ItalyDavid Tuveson, Cold Spring Harbor, NY, USABreast cancer, early stageChair: Nadia Harbeck, Munich, GermanyHerve Bonnefoi, Bordeaux, FranceFatima Cardoso, Lisbon, PortugalMarco Colleoni, Milan, ItalyJavier Cortes, Madrid, SpainCarlos Caldas, Cambridge, UKCarsten Denkert, Berlin, GermanyAngelo di Leo, Prato, ItalyDoug Easton, Cambridge, UKMichael Gnant, Vienna, AustriaJos Jonkers, Amsterdam, NetherlandsOlivia Pagani, Bellinzona, SwitzerlandElzbieta Senkus, Gda nsk, PolandAndrew Tutt, London, UKBreast cancer, metastaticChair: Fabrice André, Villejuif, FranceJoan Albanell, Barcelona, SpainThomas Bachelot, Lyon, FranceFatima Cardoso, Lisbon, PortugalRob Clarke, Philadelphia, PA, USASherene Loi, Melbourne, AustraliaSibylle Loibl, Neu-Isenburg, GermanyFrederique Penault-Llorca, Clermont-Ferrand, FranceAleix Prat, Barcelona, SpainRoman Rouzier, Paris, FrancePeter Schmid, London, UKBritta Weigelt, New York, NY, USALucy Yates, Cambridge, UKCNS tumoursChair: Michael Weller, Zurich, SwitzerlandCarmen Bala na, Barcelona, SpainAlba Brandes, Bologna, ItalyLouis Chesler, London, UKPim French, Rotterdam, NetherlandsEmilie Le Rhun, Lille, FranceRoger Henriksson, Stockholm, SwedenStefan Pfister, Hedielberg, GermanyMatthias Preusser, Vienna, AustriaJörg-Christian Tonn, Munich, GermanyMartin van den Bent, Rotterdam, NetherlandsPatrick Wen, Boston, MA, USAWolfgang Wick, Heidelberg, Germany
Developmental therapeuticsChair: Jan Schellens, Amsterdam, NetherlandsAlex A. Adjei, Rochester, MN, USAUdai Banerji, London, UKChristian Blank, Amsterdam, NetherlandsAnthony Chalmers, Glasgow, UKMaria Grazia Daidone, Milan, ItalyAntoine Italiano, Bordeaux, FranceUlrik Lassen, Copenhagen, DenmarkIgnacio Melero, Pamplona, SpainRuth Plummer, Newcastle upon Tyne, UKJordi Rod on, Houston, TX, USATeresa Troiani, Naples, ItalyIan Waddell, Manchester, UKGastrointestinal tumours, colorectalChair: Volker Heinemann, Munich, GermanyRichard Adams, Cardiff, UKDirk Arnold, Lisbon, PortugalAndrés Cervantes, Valencia, SpainAlfredo Falcone, Pisa, ItalyGunnar Folprecht, Dresden, GermanyRob Glynne-Jones, Northwood, UKThomas Gruenberger, Vienna, AustriaRienk Offringa, Heidelberg, GermanyPer Pfeiffer, Odense, DenmarkOwen Sansom, Glasgow, UKJulien Taieb, Paris, FranceVincenzo Valentini, Rome, ItalyGastrointestinal tumours, non-colorectalChair: Eric Van Cutsem, Leuven, BelgiumFatima Carneiro, Porto, PortugalStefano Cascinu, Modena, ItalyDavid Cunningham, Sutton, UKManuel Hidalgo, Madrid, SpainClaus Jorgensen, Manchester, UKYoon-Koo Kang, Seoul, Republic of KoreaFlorian Lordick, Leipzig, GermanyChristophe Mariette†, Lille, FranceArnaud Roth, Geneva, SwitzerlandDieter Saur, Munich, GermanyThomas Seufferlein, Ulm, GermanyMarcel Verhej, Amsterdam, NetherlandsMarc Ychou, Montpellier, FranceGenitourinary tumours, prostateChair: Johann de Bono, Sutton, UKAndrea Alimonti, Bellinzona, SwitzerlandEsther Baena, Manchester, UKHimisha Beltran, New York, NY, USAWinald Gerritsen, Nijmegen, NetherlandsSilke Gillessen, St. Gallen, SwitzerlandNicholas James, Birmingham, UKVesa Kataja, Jyv askyl a, FinlandDavid Lorente, Valencia, SpainDavid Olmos, Madrid, SpainStephane Oudard, Paris, FranceScott Tomlins, Ann Arbor, MI, USADavid Waugh, Belfast, UKGenitourinary tumours, non-prostateChair: Bernard Escudier, Villejuif, FranceCory Abate-Shen, New York, NY, USALaurence Albiges, Villejuif, FranceAris Bamias, Athens, GreeceAxel Bex, Amsterdam, NetherlandsPetri Bono, Helsinki, FinlandFernando Calais da Silva, Lisbon, PortugalMaria De Santis, Coventry, UKKarim Fizazi, Villejuif, FranceVincent Khoo, London, UKAntonio L opez-Beltran, Lisbon, PortugalAndrea Necchi, Milan, ItalyCamillo Porta, Pavia, ItalyMichael Staehler, Munich, GermanyGynaecological cancersChair: Domenica Lorusso, Milan, ItalyFrederic Amant, Leuven, BelgiumSusana Banerjee, London, UKAntonio Gonz alez-Mart ın, Madrid, SpainPhilipp Harter, Essen, GermanyMansoor Mirza, Copenhagen, DenmarkRemi A Nout, Leiden, NetherlandsSandro Pignata, Naples, ItalyJamie Prat, Barcelona, SpainIsabelle Ray-Coquard, Lyon, FranceIgnace Vergote, Leuven, Belgium
Haematological malignanciesChair: Mariano Provencio, Madrid, SpainChristian Buske, Ulm, GermanyMaria del Mar C ordoba, Madrid, SpainAndrés Ferreri, Milan, ItalyJuan Fernando Garcia, Madrid, SpainPaolo Ghia, Milan, ItalyMichele Ghielmini, Bellinzona, SwitzerlandJosé Gomez Codina, Valencia, SpainMarco Ladetto, Alessandria, ItalySteven Le Gouill, Nantes, FranceFrederic Peyrade, Nice, FranceTim Somervaille, Manchester, UKEvangelos Terpos, Athens, GreeceAndreas Trumpp, Heidelberg, GermanyHead and neck cancerChair: Jean-Pascal Machiels, Brussels, BelgiumAmparo Cano, Madrid, SpainIsabel Fonseca, Lisbon, PortugalVincent Grégoire, Brussels, BelgiumJoel Guigay, Nice, FranceChristophe Le Tourneau, Paris, FranceLisa Licitra, Milan, ItalyMarco Merlano, Cuneo, ItalyRicardo Mesia, Barcelona, SpainSjoukje Oosting, Groningen, NetherlandsAmanda Psyrri, Athens, GreeceHans-Peter Rodemann, Tübingen, GermanyChristian Simon, Lausanne, SwitzerlandImmunotherapy of cancerChair: Inge Marie Svane, Herlev, DenmarkMario Colombo, Milan, ItalyGeorge Coukos, Lausanne, SwitzerlandJérôme Galon, Paris, FranceHelen Gogas, Athens, GreeceJohn Haanen, Amsterdam, NetherlandsGuido Kroemer, Paris, FrancePaul Nathan, Northwood, UKEli Pikarsky, Jerusalem, IsraelThomas Powles, London, UKDaniel Speiser, Lausanne, SwitzerlandFiona Thistlethwaite, Manchester, UKMelanoma and other skin tumoursChair: Reinhard Dummer, Zurich, SwitzerlandPaolo Ascierto, Naples, ItalyBoris Bastian, San Francisco, CA, USAMatthias Guckenberger, Zurich, SwitzerlandPaul Lorigan, Manchester, UKSalvador Martin-Algarra, Pamplona, SpainOlivier Michielin, Lausanne, SwitzerlandDaniel Peeper, Amsterdam, NetherlandsAntoni Ribas, Los Angeles, CA, USACaroline Robert, Villejuif, FranceYardena Samuels, Rehovot, IstraelDirk Schadendorf, Essen, GermanyAlessandro Testori, Milan, ItalyNETs and endocrine tumoursChair: Michel Ducreux, Villejuif, FranceEric Baudin, Villejuif, FranceJerome Bertherat, Paris, FranceFelix Beuschlein, Munich, GermanyJaume Capdevila, Barcelona, SpainIan Chau, Sutton, UKRocio Garcia-Carbonero, Madrid, SpainDik Kwekkeboom†, Rotterdam, NetherlandsMarianne Pavel, Erlangen, GermanyGuido Rindi, Rome, ItalyEnrico Ruffini, Turin, ItalyJonathan Strosberg, Tampa, FL, USANon-metastatic NSCLC and other thoracicmalignanciesChair: Pilar Garrido, Madrid, SpainPaul Baas, Amsterdam, NetherlandsMariano Barbacid, Madrid, SpainAnne-Marie Dingemans, Maastricht, NetherlandsMarina Garassino, Milan, ItalyCécile Le Péchoux, Villejuif, FranceKeunchil Park, Seoul, Republic of KoreaLuis Paz-Ares, Madrid, SpainSanjay Popat, London, UKEgbert Smit, Amsterdam, NetherlandsPaul Van Schil, Edegem, BelgiumJohan Vansteenkiste, Leuven, BelgiumEmmy Verschuren, Helsinki, Finland
NSCLC, metastaticChair: Rafal Dziadziuszko, Gdansk, PolandBenjamin Besse, Villejuif, FranceOdd Terje Brustugun, Oslo, NorwayCaroline Dive, Manchester, UKEnriqueta Felip, Barcelona, SpainKeith Kerr, Aberdeen, UKTony S.K. Mok, Hong Kong, ChinaSolange Peters, Lausanne, SwitzerlandMartin Reck, Grosshansdorf, GermanyGaetano Rocco, Naples, ItalyCharles Rudin, New York, NY, USASuresh Senan, Amsterdam, NetherlandsLecia V. Sequist, Boston, MA, USAJean-Charles Soria, Villejuif, FrancePublic health policy and health economicsChair: Paolo G. Casali, Milan, ItalyPeter Boyle, Ecully, FranceHarry de Koning, Rotterdam, NetherlandsElisabeth de Vries, Groningen, NetherlandsAlex Eniu, Cluj-Napoca, RomaniaRosa Giuliani, Rome, ItalyMaarten IJzerman, Enschede, NetherlandsYolande Lievens, Ghent, BelgiumJosé Maria Martin Moreno, Valencia, SpainRichard Sullivan, London, UKCarin Uyl-de Groot, Rotterdam, NetherlandsSarcomaChair: Jean-Yves Blay, Lyon, FranceSebastian Bauer, Essen, GermanySylvie Bonvalot, Paris, FranceA. Paolo Dei Tos, Treviso, ItalyGeorge Demetri, Boston, MA, USAMikael Eriksson, Lund, SwedenHans Gelderblom, Leiden, NetherlandsRick Haas, Amsterdam, NetherlandsHeikki Joensuu, Helsinki, FinlandRobin Jones, London, UKJavier Martin Broto, Seville, SpainPoul Sorensen, Vancouver, BC, CanadaSilvia Stacchiotti, Milan, ItalySupportive and palliative careChair: Matti Aapro, Genolier, SwitzerlandAndreas Charalambous, Limassol, CyprusPere Gascon, Barcelona, SpainJoern Herrstedt, Odense, DenmarkJane Hopkinson, Cardiff, UKKarin Jordan, Heidelberg, GermanyStein Kaasa, Oslo, NorwayBernardo Rapoport, Johannesburg, South AfricaTina Saarto, Helsinki, FinlandFlorian Scotté, Paris, FranceAnton Snegovoy, Moscow, Russian FederationKazuo Tamura, Fukuoka, JapanDeclan Walsh, Dublin, IrelandTranslational ResearchChairs: Charles Swanton, London, UK andJoan Seoane, Barcelona, SpainGerhardt Attard, Sutton, UKCarlos Caldas, Cambridge, UKRodrigo Dienstmann, Barcelona, SpainCaroline Dive, Manchester, UKRaffaella Giavazzi, Milan, ItalyMonika Hegi, Epalinges, SwitzerlandThomas Helleday, Stockholm, SwedenJohanna Joyce, Lausanne, SwitzerlandIlaria Malanchi, London, UKSergio Quezada, London, UKSohrab Shah, Vancouver, BC, CanadaSheila Singh, Hamilton, ON, CanadaYinyin Yuan, London, UKThe European Society for Medical Oncology wishes to express its appreciation and gratitude to all of the above experts for their majoreffort in reviewing and selecting the content of this Abstract Book.
ACKNOWLEDGEMENTESMO gratefully acknowledges the valuable contribution of the following organisations in the ESMO 2017Congress through their presence in the exhibition hall, organisation of satellite symposia sessions, or viasponsorship activities (as of August 2017).AbbVie, Inc.Chiltern International LtdLeCancer.frPfizer OncologyAccelovanceClinerionLife LengthPharmaMar, S.A.Advanced AcceleratorApplicationsClinical Research Malaysia (CRM)Lilly OncologyPharmanovia A/SClovis OncologyLinicalPhillips Molecular Pathway DxColor GenomicsLunitPierre Fabre MedicamentCya
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain Volume 28 Supplement 5 September 2017. The European Society for Medical Oncology (ESMO) ESMO is the leading professional organisation for medical oncology, with the overarching goal of improving outcomes for cancer
